Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
NCT01037517
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Lymphoma
Interventions
DRUG:
Plerixafor
OTHER:
Observation: Nonintervention
Sponsor
CancerCare Manitoba